Formed by a cadre of veterans from Baxter Healthcare’s renal division, Sorbent Therapeutics Inc. is developing polymer drugs that treat disease through the management of sodium and fluid volume in the body. Those two factors, along with potassium reduction or retention depending upon the condition, are keys to addressing a string of related illnesses including end-stage renal disease and congestive heart failure. Sorbent’s polymer drugs remove sodium from the gastrointestinal tract but are not absorbed into the rest of the bloodstream, thereby minimizing any number of potential toxicity, bioavailability and metabolism risks.
750 East Bunker Court
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The AstraZeneca CEO again calls for rich European countries to pay more for new drugs because "a model where the US funds innovation in our industry for the entire world doesn't work."
The AKT inhibitor proves ineffective for metastatic castration-resistant disease in a Phase III trial.
